Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128727) titled 'Early Management for Anti-Angiogenic Drug-Related Proteinuria in Hepatocellular Carcinoma: A Prospective, Randomized, Controlled Study Aimed at Maintaining Targeted Therapy Intensity and Improving Prognosis' on July 24.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Zhongshan Hospital, Fudan University
Condition:
Liver cancer
Intervention:
Standard management group:Follow the current clinical routine, which is to do a 24-hour urine protein test only if the urine protein qualitative test is >= 2, and then decide whether to pause targeted therapy based on the result (urine protein >=...